Hims & Hers Health (HIMS) stock surged over 44% in premarket trading on Monday, March 9, 2026, following a Bloomberg report that Danish pharmaceutical giant Novo Nordisk plans to sell its weight-loss drugs through the Hims telehealth platform. The two companies are expected to announce the partnership imminently, marking a dramatic reversal from their recent legal feud.
In February, Novo Nordisk had sued Hims after the telehealth company launched a copycat version of Novo's oral Wegovy weight-loss pill, priced at $49 compared to the branded version's $149. Novo argued the product infringed on patents tied to its blockbuster semaglutide medications, Ozempic and Wegovy. The lawsuit was the latest clash, following earlier accusations from Novo that Hims continued to market compounded versions of its drugs after a prior collaboration ended.
The new agreement sees Novo Nordisk withdrawing its patent infringement lawsuit. In return, Hims will stop advertising compounded GLP-1 drugs and will instead distribute Novo's FDA-approved injectable and oral semaglutide medicines on its platform at standard market prices. Hims CEO Mike Doustdar confirmed the company dropped the court proceedings while reserving the right to revive them if necessary.
Analyst reaction was positive but cautious. Leerink's Michael Cherny called the deal "both a surprise and an unabashed positive for HIMS’ stock," noting it may prevent a protracted legal battle. However, he maintained a Market Perform rating, stating it was not a "clearing event" for the company's growth potential. Morgan Stanley's Craig Hettenbach highlighted that the partnership could ease the significant legal and regulatory overhang that had made HIMS a heavily shorted stock, potentially leading to a strong rebound.
The conflict originated from a regulatory loophole that allowed telehealth companies to sell compounded copies of branded drugs during official shortages. While Novo has since resolved its supply constraints, some platforms, including Hims, continued offering compounded versions by tweaking dosages. The new partnership signifies a strategic shift for drugmakers, increasingly using online platforms like Hims as a major channel to reach patients seeking obesity treatments.
